Everything below concerns Thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
(The total force applied to the longer dam will be greater, due to the greater total surface area for the pressure to act upon. But for a given 5-foot (1.5 m)-wide section of each dam, the 10 ft (3.0 m) deep water will apply one quarter the force of 20 ft (6.1 m) deep water). A person will feel the same pressure whether their head is dunked a metre beneath the surface of the water in a small pool or to the same depth in the middle of a large lake. If four interconnected vases contain different amounts of water but are all filled to equal depths, then a fish with its head dunked a few centimetres under the surface will be acted on by water pressure that is the same in any of the vases. If the fish swims a few centimetres deeper, the pressure on the fish will increase with depth and be the same no matter which vase the fish is in. If the fish swims to the bottom, the pressure will be greater, but it makes no difference which vase it is in. All vases are filled to equal depths, so the water pressure is the same at the bottom of each vase, regardless of its shape or volume. If water pressure at the bottom of a vase were greater than water pressure at the bottom of a neighboring vase, the greater pressure would force water sideways and then up the neighboring vase to a higher level until the pressures at the bottom were equalized. Pressure is depth dependent, not volume dependent, so there is a reason that water seeks its own level. Restating this as an energy equation, the energy per unit volume in an ideal, incompressible liquid is constant throughout its vessel.
He criticised Israel for its attacks on government and civilians and expressed gratitude for American, Arab, and Turkish mediators for de-escalating the conflict and said that "the Israeli entity resorted to a wide-scale targeting of civilian and government facilities", adding that it led to a "significant complication of the situation and pushed matters to a large-scale escalation". On 16 July 2025, US Secretary of State Marco Rubio stated that the United States was making progress for a ceasefire agreement including Israel, saying "We hope to see some real progress to end what you've been seeing over the last couple of hours", as he addressed reporters at the Oval Office. According to a Turkish security source, Turkish intelligence officers held talks with Syrian Druze leaders for securing the ceasefire. İbrahim Kalın, the director of the Turkish National Intelligence Organization, also held discussions with his Israeli, American and Syrian counterparts, as well as Ahmed al-Sharaa. A joint "Gulf-Arab-Turkish" statement reaffirmed their support for Syrian integrity and "welcomed" al-Sharaa's commitment to hold to account fighters who took part in "abuses". According to the spiritual leadership of the Druze in Syria, the agreement signed for a ceasefire from 19 July included a number of key steps intended to bring about calm and an end to the conflicts in the area.
having an acceptable treatment protocol in place that changes the outcome for patients diagnosed early with the disease an understanding of the condition's natural history an understanding about who will be treated as a patient a screening test that is reliable for both affected and unaffected patients and is acceptable to the public As diagnostic techniques have progressed, debates have arisen as to how screening programs should adapt. Tandem mass spectrometry has greatly expanded the potential number of diseases that can be detected, even without satisfying all of the other criteria used for making screening decisions. Duchenne muscular dystrophy is a disease that has been added to screening programs in several jurisdictions around the world, despite the lack of evidence as to whether early detection improves the clinical outcome for a patient.
BRD-6929 is a selective inhibitor of HDAC1 and HDAC2, with IC50Tooltip half-maximal inhibitory concentration values of 1 nM and 8–30 nM, respectively, and with 30- to 400-fold selectivity over HDAC3 (IC50 = 398–458 nM) and no inhibition of HDAC8 or class II HDACs (IC50 = >30,000 nM). However, although originally reported to be selective for inhibition of HDAC1 and HDAC2 over HDAC3, subsequent research has found that BRD-6929 is not in fact selective over HDAC3, with previous findings being claimed to have been an assay artifact. As a result, BRD-6929 is no longer recommended as a selective HDAC1 and HDAC2 inhibitor. The drug shows slow-on/slow-off binding kinetics and hence more sustained HDAC inhibition, unlike other HDAC inhibitors like the fast-on/fast-off vorinostat (SAHA) and entinostat (MS-275). Aside from the HDACs, it also showed no binding at 80 other targets at a concentration of 10,000 nM. BRD-6929 produces antidepressant-like and mood-stabilizing-like effects in rodents. This included reducing immobility in the forced swim test (FST) and attenuating amphetamine-induced hyperlocomotion without affecting basal locomotor activity. Conversely, vorinostat was ineffective in these tests. In addition, vorinostat showed dissimilar and lesser effects on gene transcription compared to BRD-6929. These differences may be related to selectivity and duration of exposure, with sustained exposure as with BRD-6929 possibly being advantageous.
Sources: en.wikipedia.org
Surfactants play an important role in droplet-based microfluidics. The main purpose of using a surfactant is to reduce the interfacial tension between the dispersed phase (droplet phase, typically aqueous) and continuous phase (carrier liquid, typically oil) by adsorbing at interfaces and preventing droplets from coalescing with each other, therefore stabilizing the droplets in a stable emulsion state, which allows for longer storage times in delay-lines, reservoirs, or vials. Without using surfactants, the unstable emulsions will eventually evolve into separate phases to reduce the overall energy of the system. Surface chemistry cannot be ignored in microfluidics as the interfacial tension becomes a major consideration among microscale droplets. Linas Mazutis and Andrew D. Griffiths presented a method that used surfactants to achieve a selective and highly controllable coalescence without external manipulation. They manipulate the contact time and the interfacial surfactant coverage of a drop pair to control droplet fusion. The larger the difference percentage of the interfacial surfactant coverage between two droplets, the less likely coalescence will occur. This method allowed researchers to add reagents to droplets in a different way and further study the emulsification.
Light output is approximately proportional to V 3.4 Power consumption is approximately proportional to V 1.6 Lifetime is approximately proportional to V −16 Color temperature is approximately proportional to V 0.42 A 5% reduction in voltage will double the life of the bulb, but reduce its light output by about 16%. Long-life bulbs take advantage of this trade-off in applications such as traffic signal lamps. Since electric energy they use costs more than the cost of the bulb, general service lamps emphasize efficiency over long operating life. The objective is to minimize the cost of light, not the cost of lamps. Early bulbs had a life of up to 2500 hours, but in 1924 the Phoebus cartel agreed to limit life to 1000 hours. When this was exposed in 1953, General Electric and other leading American manufacturers were banned from limiting the life. The relationships above are valid for only a few percent change of voltage around standard rated conditions, but they indicate that a lamp operated at low voltage could last much longer than at rated voltage, albeit with greatly reduced light output. The "Centennial Light" is a light bulb that is accepted by the Guinness Book of World Records as having been burning almost continuously at a fire station in Livermore, California, since 1901. However, the bulb emits the equivalent light of a four watt bulb. A similar story can be told of a 40-watt bulb in Texas that has been illuminated since 21 September 1908.
== Variation == While the citric acid cycle is in general highly conserved, there is significant variability in the enzymes found in different taxa (note that the diagrams on this page are specific to the mammalian pathway variant). Some differences exist between eukaryotes and prokaryotes. The conversion of D-threo-isocitrate to 2-oxoglutarate (α-ketoglutarate) is catalyzed in eukaryotes by the NAD+-dependent EC 1.1.1.41, while prokaryotes employ the NADP+-dependent EC 1.1.1.42. Similarly, the conversion of (S)-malate to oxaloacetate is catalyzed in eukaryotes by the NAD+-dependent EC 1.1.1.37, while most prokaryotes utilize a quinone-dependent enzyme, EC 1.1.5.4. A step with significant variability is the conversion of succinyl-CoA to succinate. Most organisms utilize EC 6.2.1.5, succinate–CoA ligase (ADP-forming) (despite its name, the enzyme operates in the pathway in the direction of ATP formation). In mammals a GTP-forming enzyme, succinate–CoA ligase (GDP-forming) (EC 6.2.1.4) also operates. The level of utilization of each isoform is tissue dependent. In some acetate-producing bacteria, such as Acetobacter aceti, an entirely different enzyme catalyzes this conversion – EC 2.8.3.18, succinyl-CoA:acetate CoA-transferase. This specialized enzyme links the TCA cycle with acetate metabolism in these organisms. Some bacteria, such as Helicobacter pylori, employ yet another enzyme for this conversion – succinyl-CoA:acetoacetate CoA-transferase (EC 2.8.3.5). Some variability also exists at the previous step – the conversion of 2-oxoglutarate to succinyl-CoA.
denotes contact. The second assumption in contact mechanics is related to the fact, that no tension force is allowed to occur within the contact area (contacting bodies can be lifted up without adhesion forces). This leads to an inequality which the stresses have to obey at the contact interface. It is formulated for the normal stress
The primary media outlet is the daily newspaper Albany Democrat-Herald which is owned and published by Lee Enterprises. The Democrat-Herald started as a political tool for one of Oregon's first senators. The Democrat-Herald traces its origin to the Albany Democrat newspaper, founded by Delazon Smith in 1859. Lee Enterprises also publishes the Mid-Valley Times, the Sunday version of the paper.
Sources: en.wikipedia.org
== History == Insulin was introduced by Frederick Banting and Charles Best from the University of Toronto in 1921 as an injectable agent. Researchers first reported the concept of "smart insulin patch" in 2015. The prototype of smart insulin patch "was demonstrated as a continuous glucose control in a type 1 diabetic mouse model. As of 2019, glucose-responsive insulin patches are becoming more common. In 2020, scientists at UCLA and Zenomics Inc. developed "Smart Insulin Patch 2.0" and validated its feasibility in a diabetic minipig model. Currently, Zenomics is applying for U.S. Food and Drug Administration (FDA) approval for first-in-human trials and the technology has been accepted into the FDA's Emerging Technology Program.
== Reception == The museum has consistently received favorable press. The Kansas City Star named it "Rookie of the Year" in 1992 after having received over 20,000 visitors in two months. As of 2013, it continued to draw more than 80,000 visitors per year. It is described by the Wall Street Journal as "fascinating" museum with an "enthralling" story. US News & World Report ranks it number one on its list of "Best Things To Do in Kansas City". After remodeling the ceiling and displays in January 2013, the museum was awarded "Best Remodel" by local weekly publication The Pitch.
Security enhancements Hotfix installer and notification Improved scheduler (based on a version of quartz) Improved web services support (WSDL 2.0, SOAP 1.2) Support for HTML5 web sockets Tomcat integration Support for RESTful web services Language enhancements (closures, and more) Search integration with Apache Solr HTML5 video player and Adobe Flash Player Flex and Adobe AIR lazy loading XPath integration HTML5 enhancements Additional new or improved features in ColdFusion Enterprise or Developer editions include (but are not limited to):
(p) .signature (UNIX shell/Internet standard file name) (a/i) Special Interest Group (a/i) Strasbourg Illkirch-Graffenstaden Basket (French basketball club) SIGCAT – (a) Special Interest Group for CD-ROM Applications and Technology SIGINT – (p) Signals Intelligence SIGMET – (p) Significant Meteorological Information SIIT (i) Saskatchewan Indian Institute of Technologies (Canadian university) Sirindhorn International Institute of Technology (Thai university) Stateless IP/ICMP Translation algorithm SIMAC – (a) Semantic Interaction with Music Audio Contents SIMLAS – (p) Soldier Integrated Multipurpose Laser System SIMM – (a) Single In-line Memory Module SIMNET – (p) SIMulator NETwork, later SIMulation NETwork SIMNET-D - (p) SIMNET-Developmental SIMP – (a) Strongly Interacting Massive Particle SIMPLE (a) Satellite Interactive Multimedia Platform for Low-cost Earth stations (p) Savings Incentive Match Plan for Employees (as used in SIMPLE IRA) (a) Standard Interface for Multiple Platform Link Evaluation (NATO STANAG 5602) sin – (s) Sinhala language (ISO 639-2 code) SIN – (a) Social insurance number (Canada) SINCGARS – (p) SINgle Channel Ground and Airborne Radio System SIP (i) Session Initiation Protocol State Implementation Plan System Improvement Program Systematic investment plan SIPP – (a) Self-Invested Personal Pension Siri – (a) Speech Interpretation and Recognition Interface (Apple iOS software) SIRI – (a) Service Interface for Real Time Information SIRS — (a) Systemic inflammatory response syndrome SiS – (i) Silicon Integrated Systems SIS – (i) UK Secret Intelligence Service (also known as MI6) SISO (a) Simulation Interoperability Standards Organization Society of Independent Show Organizers SIW – (i) Simulation Interoperability Workshop SIYSS – (i) Stockholm International Youth Science Seminar
Unlike most arbuscular mycorrhizal fungi, EcM fungi reproduce sexually and produce visible fruiting bodies in a wide variety of forms. The fruiting body, or sporocarp, can be thought of as an extension of the extraradical hyphae. Its cell walls and spores are typically composed of complex carbohydrates, and often incorporate a great deal of nitrogen. Many EcM fungi can only form fruiting bodies and complete their life cycles by participating in an EcM relationship. The fruit bodies of many species take on classic, well-recognized shapes such as epigeous mushrooms and hypogeous truffles. Most of these produce microscopic propagules of about 10 μm that can disperse over large distances by way of various vectors, ranging from wind to mycophagous animals. It has been suggested that animals are drawn to hypogeous fruiting bodies because they are rich in nutrients such as nitrogen, phosphorus, minerals and vitamins. However, others argue that the specific nutrients are less important than the availability of food at specific times of the year. Surveys of fruiting bodies have been used to assess community composition and richness in many studies. However, this method is imperfect as fruiting bodies do not last long and can be hard to detect.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.